Cytek Biosciences/$CTKB

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Cytek Biosciences

Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.

Ticker

$CTKB
Sector
Primary listing

Employees

688

CTKB Metrics

BasicAdvanced
$511M
-
-$0.05
1.34
-

What the Analysts think about CTKB

Analyst ratings (Buy, Hold, Sell) for Cytek Biosciences stock.

Bulls say / Bears say

Cytek expanded its installed base to 3,295 instruments in Q2 2025, adding 146 units and achieving 3% year-over-year unit growth, underscoring strong market adoption of its FSP technology (GlobeNewswire).
In Q2 2025, recurring revenue from services and reagents grew 16% year-over-year to comprise 32% of trailing 12-month total revenue, enhancing revenue stability and visibility (Comtex).
As of June 30, 2025, Cytek held $262.0 million in cash and marketable securities, providing ample liquidity to fund operations and future R&D investments (Nasdaq).
Total revenue for Q2 2025 declined 2% year-over-year to $45.6 million, reflecting ongoing softness in instrument sales in EMEA and APAC markets (GlobeNewswire).
The company reported a net loss of $5.6 million in Q2 2025, indicating persistent profitability challenges despite improving operational leverage (Nasdaq).
Cytek narrowed its full-year 2025 revenue guidance to $196 million–$205 million, implying potential flat to 2% growth, which may disappoint investors seeking stronger expansion (GlobeNewswire).
Data summarised monthly by Lightyear AI. Last updated on 8 Oct 2025.

CTKB Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

CTKB Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $CTKB

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs